Zobrazeno 1 - 10
of 54
pro vyhledávání: '"LK Roskos"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 6, Iss 4, Pp 249-257 (2017)
Benralizumab is a humanized, afucosylated, anti‐interleukin‐5 receptor α, immunoglobulin G (IgG) 1 κ monoclonal antibody. We developed a population pharmacokinetic (PK)/pharmacodynamic (PD) model for benralizumab by analyzing PK and blood eosin
Externí odkaz:
https://doaj.org/article/5c526d62e9534d74955d9160cd7239af
Autor:
Zhang N; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA., Chan ML; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA., Li J; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (CPSS), R&D, AstraZeneca, South San Francisco, California, USA., Brohawn PZ; Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceutical R&D, AstraZeneca, Gaithersburg, Maryland, USA., Sun B; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (CPSS), R&D, AstraZeneca, South San Francisco, California, USA., Vainshtein I; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (CPSS), R&D, AstraZeneca, South San Francisco, California, USA., Roskos LK; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (CPSS), R&D, AstraZeneca, South San Francisco, California, USA., Faggioni R; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (CPSS), R&D, AstraZeneca, South San Francisco, California, USA., Savic RM; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Dec; Vol. 12 (12), pp. 1945-1959. Date of Electronic Publication: 2023 Oct 06.
Autor:
Huang Y; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, 121 Oyster Point Boulevard, South San Francisco, CA 94080, USA., Yuan J; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, 121 Oyster Point Boulevard, South San Francisco, CA 94080, USA., Mu R; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, 121 Oyster Point Boulevard, South San Francisco, CA 94080, USA., Kubiak RJ; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA., Ball K; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Granta Park, Cambridge CB21 6GH, UK., Cao M; Department of Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA., Hussmann GP; Department of Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA., de Mel N; Department of Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA., Liu D; Department of Analytical Sciences, Biopharmaceutical Development, R&D, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA., Roskos LK; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA., Liang M; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, 121 Oyster Point Boulevard, South San Francisco, CA 94080, USA., Rosenbaum AI; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, 121 Oyster Point Boulevard, South San Francisco, CA 94080, USA.
Publikováno v:
Antibodies (Basel, Switzerland) [Antibodies (Basel)] 2023 Oct 17; Vol. 12 (4). Date of Electronic Publication: 2023 Oct 17.
Autor:
Ly NS; Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, CA, 94502, USA. nly@exelixis.com., Li J; Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, CA, 94502, USA., Faggioni R; Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, CA, 94502, USA., Roskos LK; Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, CA, 94502, USA., Brose MS; Sidney Kimmel Cancer Center, Jefferson Health Northeast, Philadelphia, PA, USA.
Publikováno v:
Clinical pharmacokinetics [Clin Pharmacokinet] 2023 Apr; Vol. 62 (4), pp. 587-598. Date of Electronic Publication: 2023 Mar 04.
Autor:
Wang B; Amador Bioscience, Pleasanton, California, USA., Goodman J; Clinical Pharmacology and Safety Sciences, AstraZeneca, BioPharmaceuticals, R&D, Cambridge, UK., Roskos LK; Clinical Pharmacology and Safety Sciences, AstraZeneca, BioPharmaceuticals, R&D, Gaithersburg, Maryland, USA.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2022 Apr; Vol. 11 (4), pp. 438-446. Date of Electronic Publication: 2022 Jan 12.
Autor:
Arends R; Clinical Pharmacology & Safety Sciences, AstraZeneca, Gaithersburg, MD, USA., Guo X; Clinical Pharmacology & Safety Sciences, AstraZeneca, Gaithersburg, MD, USA., Baverel PG; Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, UK., González-García I; Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, UK., Xie J; Clinical Pharmacology & Safety Sciences, AstraZeneca, Gaithersburg, MD, USA., Morsli N; Clinical Development, AstraZeneca, Cambridge, UK., Yovine A; Clinical Development, AstraZeneca, Cambridge, UK., Roskos LK; Clinical Pharmacology & Safety Sciences, AstraZeneca, Gaithersburg, MD, USA.
Publikováno v:
Oncoimmunology [Oncoimmunology] 2021 Mar 17; Vol. 10 (1), pp. 1898104. Date of Electronic Publication: 2021 Mar 17.
Autor:
Cheng J; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA 94080, USA., Liang M; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA 94080, USA., Carvalho MF; Antibody Discovery & Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Granta Park, Cambridge CB21 6GH, UK., Tigue N; Antibody Discovery & Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Granta Park, Cambridge CB21 6GH, UK., Faggioni R; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA 94080, USA., Roskos LK; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA 94080, USA., Vainshtein I; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA 94080, USA.
Publikováno v:
Antibodies (Basel, Switzerland) [Antibodies (Basel)] 2020 Sep 18; Vol. 9 (3). Date of Electronic Publication: 2020 Sep 18.
Autor:
Zhang J; AstraZeneca PLC. Electronic address: Jianchun.zhang@astrazeneca.com., Arends RH; AstraZeneca PLC., Kubiak RJ; AstraZeneca PLC., Roskos LK; AstraZeneca PLC., Liang M; AstraZeneca PLC., Lee N; AstraZeneca PLC., Chen CC; AstraZeneca PLC., Yang H; AstraZeneca PLC.
Publikováno v:
Journal of immunological methods [J Immunol Methods] 2020 Sep - Oct; Vol. 484-485, pp. 112817. Date of Electronic Publication: 2020 Jun 29.
Autor:
Kubiak RJ; Clinical Pharmacology and Safety Sciences, AstraZeneca PLC 1, One MedImmune Way, Gaithersburg, MD 20878, USA., Arends RH; Clinical Pharmacology and Safety Sciences, AstraZeneca PLC 1, One MedImmune Way, Gaithersburg, MD 20878, USA., Lee N; Clinical Pharmacology and Safety Sciences, AstraZeneca PLC 1, One MedImmune Way, Gaithersburg, MD 20878, USA., Liang M; Clinical Pharmacology and Safety Sciences, AstraZeneca PLC 1, 121 Oyster Point Blvd, South San Francisco, CA 94080, USA., Zhang J; Clinical Pharmacology and Safety Sciences, AstraZeneca PLC 1, One MedImmune Way, Gaithersburg, MD 20878, USA., Roskos LK; Clinical Pharmacology and Safety Sciences, AstraZeneca PLC 1, One MedImmune Way, Gaithersburg, MD 20878, USA.
Publikováno v:
Bioanalysis [Bioanalysis] 2020 Feb; Vol. 12 (4), pp. 245-256. Date of Electronic Publication: 2020 Feb 24.
Autor:
Vainshtein I; BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA 94080, USA. Electronic address: inna.vainshtein@astrazeneca.com., Sun B; BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA 94080, USA., Roskos LK; BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA 94080, USA., Liang M; BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA 94080, USA. Electronic address: meina.liang@astrazeneca.com.
Publikováno v:
Journal of immunological methods [J Immunol Methods] 2020 Feb; Vol. 477, pp. 112688. Date of Electronic Publication: 2019 Oct 30.